Beractant

Beractant
Clinical data
Trade names	Survanta, others
AHFS/Drugs.com	Monograph
Routes of; administration	Endotracheal
ATC code	None;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Identifiers
CAS Number	108778-82-1 ;
DrugBank	DB06761 ;
ChemSpider	none;
UNII	S866O45PIG;
KEGG	D03096;
ChEMBL	ChEMBL1201624 ;
CompTox Dashboard (EPA)	DTXSID70883180 ;
	(what is this?) (verify)

Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.^[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.^[2] Survanta is manufactured by Abbvie.

Trade namesSurvanta, others

AHFS/Drugs.comMonograph

Routes of
administrationEndotracheal

ATC code

None

Quick facts Clinical data, Trade names ...

Close

Beractant is on the World Health Organization's List of Essential Medicines.^[3]

[1]

[2]

[3]

Beractant

Generic form

References

Related Articles